1. Introduction {#sec1-brainsci-07-00080}
===============

1.1. Tourette Syndrome {#sec1dot1-brainsci-07-00080}
----------------------

Once believed to be a rare disease, Tic Disorders \[[@B1-brainsci-07-00080]\]---including Tourette Syndrome---make up 1% of the population, and up to 20% in childhood \[[@B2-brainsci-07-00080]\].

The disorder mainly affects males by a male to female ratio of 3--4:1; TS begins before age 18, usually around age 6 \[[@B3-brainsci-07-00080]\]. In youth, the disorder often increases in severity peaking in the prepubertal period, while in adulthood, in 50--75% of cases, tics improve dramatically \[[@B4-brainsci-07-00080],[@B5-brainsci-07-00080],[@B6-brainsci-07-00080],[@B7-brainsci-07-00080]\].

Recently, TS studies showed high correlations of tics with behavioural disorders such as Attention Deficit Hyperactivity Disorder (ADHD), Obsessive-Compulsive Behaviours/Disorders/Symptoms (OCB/ OCD/OCS), anxiety, depression and poor impulse control e.g., SIB (Self-Injurious Behaviour) and NOSI (Non-Obscene Socially Inappropriate behaviour) \[[@B8-brainsci-07-00080]\].

Anatomically, basal ganglia and substantia nigra are considered the neuroanatomical regions associated with Tourette Syndrome (TS), Parkinson's Disease (PD) and other movement disorders. Whereas, from an etio-pathological point of view an alteration of dopaminergic synaptogenesis appears to determine TS symptoms \[[@B9-brainsci-07-00080]\].

Many famous artists were affected by TS, such as Samuel Johnson \[[@B10-brainsci-07-00080]\]. Several authors \[[@B11-brainsci-07-00080],[@B12-brainsci-07-00080],[@B13-brainsci-07-00080],[@B14-brainsci-07-00080]\] examined the possible TS diagnosis of Mozart, hypothesising that the syndrome actually contributed to the musician's creativity. However, it remains unclear if Mozart was truly affected by TS. His behaviour could have been due to a wide spectrum of neurobehavioural disorders. Zanaboni et al. \[[@B15-brainsci-07-00080]\] analysed the creative personality of a sample of 23 Italian TS subjects between 6 and 18 years old and of a healthy control group through Williams' Creativity test; by results, TS subjects obtained greater creative scores compared with controls in the Flexibility subtest. Wei \[[@B16-brainsci-07-00080]\] studied creativity in a group of 127 Taiwanese TS children and a control group of 138 Taiwanese by parents' reports. In the Elaboration subtest of Creative Thinking, TS patients were less creative than controls, whereas most TS parents reported their children to have high academic achievement.

Creativity in TS adults has never been studied in literature; for this reason, our group decided to pursue this issue in adulthood.

TS dopaminergic theory is supported by the observation of reduction or suppression of symptoms---and creativity skill, as said above---in a substantial number of patients using dopamine receptor blockers such as haloperidol or pimozide. Also, tetrabenazine, a dopamine-depleting drug that inhibits the vesicular monoamine transporter 2 (VMAT2), is effective for various hyperkinetic movement disorders, including TS \[[@B17-brainsci-07-00080],[@B18-brainsci-07-00080]\]. Results from a study on TS subjects show that after two years of tetrabenazine therapy, 80% of patients have a long-term improvement of symptoms \[[@B19-brainsci-07-00080]\]. However, more recent data are suggesting a still more complex picture, whereby also alterations in the GABAergic system may play an important role in the pathophysiology of TS \[[@B17-brainsci-07-00080]\].

1.2. Parkinson Disease {#sec1dot2-brainsci-07-00080}
----------------------

Parkinson Disease is one of the leading causes of neurological disability for individuals over 60 years of age. PD impacts an estimated 4.5 million people across the world's 10 most populous countries \[[@B20-brainsci-07-00080]\].

In PD there is a loss of dopaminergic neurons in the pars compacta of the substantia nigra (SNpc) with the presence of "Lewy bodies" due to misfolded aggregated alpha-synuclein protein.

The "cardinal signs" of PD are resting tremor, rigidity, bradykinesia-akinesia, postural instability and one-sidedness of the symptoms \[[@B21-brainsci-07-00080]\]. Patients can show freezing, i.e., the inability to start or carry on a movement \[[@B22-brainsci-07-00080]\]. Moreover, during complex and automated tasks, i.e., writing or a speech, motor control mechanisms can be lacking \[[@B23-brainsci-07-00080]\].

Also in TS subjects, complex and automatic movements can be lacking and can, therefore, generate a variety of tics, such as writing or walking or speaking or reading tics.

PD non-motor symptoms include urinary diseases issues, constipation, skin problems, sleep difficulties, cramps and paresthesia, cognitive decline, depression and other emotional changes. Depression, anxiety and emotional changes may also occur in TS patients. Actually, in a longitudinal study by Lin et al. \[[@B24-brainsci-07-00080]\] stress levels and tic severity were evaluated in a sample of 45 children with TS and/or OCD, and in a sample of 41 healthy control children. In general, psychosocial stress level was higher in patients with TS compared with the control group. Moreover, those who had higher levels of stress were more likely to have a more severe disease course and major complications. The Social Impairment component is therefore essential for TS assessment, considering that exacerbation of tics is often preceded by stressful life events.

PD treatment is principally pharmacological, i.e., dopaminergic therapy. Moreover, PD surgical treatment, i.e., Deep Brain Stimulation (DBS), is reserved for severe and refractory patients \[[@B25-brainsci-07-00080],[@B26-brainsci-07-00080]\].

More recently, Automated Mechanical Peripheral Stimulation (AMPS) is used in PD patients to treat motor deficits. This orthopedic device repetitively and automatically stimulates specific points of the foot to activate brain areas involved in the management of motor functions \[[@B27-brainsci-07-00080]\].

1.3. Creativity {#sec1dot3-brainsci-07-00080}
---------------

There is a plethora of definitions for creativity \[[@B28-brainsci-07-00080]\]. According to Tudor Powell Jones \[[@B29-brainsci-07-00080]\], creativity is the combination of flexibility, originality and ability to adopt readily new and unusual cognitive patterns in order to solve problems.

Williams' creativity model, the one used at Milan Tourette Syndrome Centre, defines creativity as the ability to generate ideas or innovative artistic products.

For several years, researchers such as Flaherty \[[@B30-brainsci-07-00080]\] have hypothesised that high dopamine levels in the mesolimbic area improves working memory, facilitating mental connections and original thoughts.

Among the different studies \[[@B31-brainsci-07-00080],[@B32-brainsci-07-00080]\], Limb and Braun \[[@B33-brainsci-07-00080]\] of the Johns Hopkins University School of Medicine in Baltimore decided to monitor the brain activity of six jazz pianists in order to find out the brain areas of creative improvisation. The authors concluded that the ability to improvise (the "peak" of creativity and self-expression) appears to be the result of a reduction of self-control and planning in the brain.

Moreover, in our clinical experience, TS patients have a strong predisposition for the arts (music, painting, expressive writing and theatre) and for jobs requiring creativity and divergent thinking.

The literature reports many cases of people at the onset of their PD who developed increased artistic skills apparently secondary to dopamine drugs \[[@B34-brainsci-07-00080]\]. Furthermore, according to the neurologist Israeli R. Inzelberg \[[@B35-brainsci-07-00080]\], patients with PD assuming dopamine suddenly manifested creative activities. In addition, an Italian research group \[[@B36-brainsci-07-00080]\] hypothesised that dopaminergic therapy could encourage creative thinking in some patients with PD.

Differently, Canesi et al. \[[@B37-brainsci-07-00080]\] evaluated whether artistic production and creative thinking are influenced by dopamine therapy or artistic skills in a sample of (1) professional artist PD patients (2) PD patients with artistic production (3) PD patients without artistic production. These groups were compared with healthy controls. Creativity scores were higher in healthy professional artists and in professional artist PD patients. PD patients without artistic production and healthy control without artistic production showed creative scores without significant difference. Creativity scores were not significantly correlated with dopamine dosage and duration. Authors suggested that further studies in "on" and "off" medication of PD patients are needed to understand these controversial results.

In this sense, fundamental appears to be the type and dose of medication of the patient because, as mentioned above, the intake of dopamine agonists can increase not only the frequency of being engaged in artistic activities, but also it changes the artistic quality of patients' creative products.

To conclude, creativity manifests itself differently in TS and PD. These diseases affect people of different ages: TS mostly affects children and adolescents \[[@B3-brainsci-07-00080]\], while PD affects adults and the elderly \[[@B20-brainsci-07-00080]\]. Based on the available data, we suppose that individuals with TS have a creative personality predisposition, unlike PD subjects who may be compromised in their creativity because of reduced production of dopamine caused by the disease. Therefore, the aim of the study is to verify the hypothesis of TS group of patients having higher creative scores than PD group of patients.

2. Materials and Methods {#sec2-brainsci-07-00080}
========================

2.1. Sample {#sec2dot1-brainsci-07-00080}
-----------

Subjects are patients of the Tourette Syndrome Centre of Milan Clinical and Research Galeazzi Hospital and of the Parkinson's Disease and Movement Disorders Unit of Pavia Mondino National Neurological Institute; patients were assessed between January 2014 and July 2016.

All participants signed the informed consent to undergo the test administration and to communicate their sensitive data for research purposes. Project identification number is n.1 of 17th November 2014. Ethics Committee was not involved as the study consisted only in a written assessment test; treatments did not vary due to the study.

The sample follows these socio-demographic characteristics:Age between 35 and 57 years old (see [Table 1](#brainsci-07-00080-t001){ref-type="table"}, [Table 2](#brainsci-07-00080-t002){ref-type="table"} and [Table 3](#brainsci-07-00080-t003){ref-type="table"});Italian subjects of both genders (see [Table 4](#brainsci-07-00080-t004){ref-type="table"});Minimum schooling requirements: high school certificate.

Inclusion criteria are:Subjects with the above-listed socio-demographic characteristics;Subjects who accepted to undergo the test administration;Diagnosis given by a specialist neurologist with diagnostic scales, i.e., YGTSS \[[@B38-brainsci-07-00080]\] in TS patients and UPDRS \[[@B39-brainsci-07-00080]\] in PD patients (see [Table 1](#brainsci-07-00080-t001){ref-type="table"}, [Table 2](#brainsci-07-00080-t002){ref-type="table"} and [Table 5](#brainsci-07-00080-t005){ref-type="table"});Patients in any certified treatment, whether no treatment, psychotherapy, drugs or DBS (see [Table 1](#brainsci-07-00080-t001){ref-type="table"} and [Table 2](#brainsci-07-00080-t002){ref-type="table"}). Drug types are heterogeneous in the sample. Patients in psychotherapy were undergoing Cognitive Behavioural Psychotherapy \[[@B8-brainsci-07-00080]\]. DBS targets in TS patients were Anterior Limb of the Internal Capsule/bed nucleus stria terminalis or Ventral oral anterior-CentroMedian/Parafascicular complex. N.B. Deep Brain Stimulation in TS patients was used to treat Obsessive-Compulsive Behaviours. DBS targets in PD patients were SubThalamic Nucleus or posterior Globus Pallidus interna.

Exclusion criteria are:The patient has not concluded the test, even partiallyOther psychiatric disorders (not considering TS and PD comorbid psychopathologies)

2.2. Age and Gender of the Sample {#sec2dot2-brainsci-07-00080}
---------------------------------

Sample average age is ([Table 3](#brainsci-07-00080-t003){ref-type="table"}) 47.48 years old (SD = 8.16); in particular, in PD subjects ([Table 3](#brainsci-07-00080-t003){ref-type="table"}) the average age is 53.03 (SD = 5.09), whereas in TS subjects ([Table 3](#brainsci-07-00080-t003){ref-type="table"}) the average age is 41.92 (SD = 6.77).

Subjects are mostly males (*n* 36 males versus *n* 18 females, see [Table 4](#brainsci-07-00080-t004){ref-type="table"}). Actually, Tourette Syndrome is mostly diffused between males \[[@B3-brainsci-07-00080]\].

TS patients' average YGTSS score is ([Table 5](#brainsci-07-00080-t005){ref-type="table"}) 46.14 (SD = 14.07); whereas PD patients' average UPDRS score is ([Table 5](#brainsci-07-00080-t005){ref-type="table"}) 89.81 (SD = 26.38).

2.3. Test ASK {#sec2dot3-brainsci-07-00080}
-------------

ASK Test by Schuler and Hell \[[@B40-brainsci-07-00080]\] Italian adaptation by Faraci and Clarotti \[[@B41-brainsci-07-00080]\] has been used to evaluate the level of creativity of the sample. The test has been chosen as it is the only available Italian test assessing creativity factor in adults.

This tool is designed to analyse how individuals face and solve problems. It includes two sections, which can be used together or separately with no limitations if separately \[[@B41-brainsci-07-00080],[@B42-brainsci-07-00080]\]:"Inferential Thinking" subtest, which investigates the analytical and logical thinking;"Creative Thinking" subtest, which investigates the creative personality.

For the present research, the participants were administrated the single subtest "Creative Thinking" because the other subtest includes graphic items and it is therefore difficult to be completed by patients with writing tics cf. TS patients \[[@B43-brainsci-07-00080]\] or with agraphia, impaired handwriting and micrographia cf. PD patients \[[@B44-brainsci-07-00080]\].

Assuming the 10 points of D.S. reported in Literature \[[@B41-brainsci-07-00080]\], we clinically hypothesised a difference of 9 points between PD and TS groups with an alpha error at 0.05 (5%) and a 0.10 beta error (90% power of the test).

Considering these parameters, the necessary sample size was found to be equal to 54 subjects in total: 27 PD subjects and 27 TS subjects.

ASK test was administered individually and patients were assisted in case of difficulties in writing (PD patients) or writing tics (TS patients). Another difficulty in the execution of the test is related to the ability to concentrate for some PD and TS patients, no measures were taken for this issue.

Subtest "Creative Thinking" consists of the following tasks:"Inventing sentences""Producing hypotheses""Defining the conditional structure""Creating categories"

2.4. Use of the Test {#sec2dot4-brainsci-07-00080}
--------------------

The administration took about 40 minutes for each subject. For each patient, ongoing treatment has been documented ([Table 1](#brainsci-07-00080-t001){ref-type="table"} and [Table 2](#brainsci-07-00080-t002){ref-type="table"}).

Each valid response obtained 1 point as score.

For each task, a total raw score has been calculated. Therefore, each patient had 5 scores: 4 task scores corresponding to the results of "Inventing phrases", "Producing hypotheses", "Defining the conditional structure", "Creating categories", and a total score for the entire ASK test "Creative Thinking".

Statistical nonparametric test employed is Mann--Whitney U test. The aim was to verify whether TS group score is statistically higher than PD group score in the tasks and in the total score, and if there is any other statistical difference considering gender and age.

3. Results and Discussion {#sec3-brainsci-07-00080}
=========================

3.1. Average ASK Results of the Sample {#sec3dot1-brainsci-07-00080}
--------------------------------------

[Table 6](#brainsci-07-00080-t006){ref-type="table"} shows average scores of TS group and PD group in the four tasks and in the total score, and Mann--Whitney U Test analysis of the scores. Patients with TS achieved an average total score of 103.1 ± 13.0, while patients with PD obtained an average total score of 94.4 ± 10.0: the difference between the two total scores is statistically significant (*p* = 0.019, see [Table 6](#brainsci-07-00080-t006){ref-type="table"}), and clinically significant as TS group score is 8.7 points higher than PD group score (see Par. Method, Subpar. Test ASK).

Also, the difference between task 1 "Inventing Sentences" (PD = 93.6 ± 7.4; TS = 99.7 ± 9.7) and task 2 "Producing Hypotheses" (PD = 95.5 ± 8.2; TS = 102.1 ± 8.3) average scores of PD and TS patients is statistically significant (*p* = 0.011 and *p* = 0.003, see [Table 6](#brainsci-07-00080-t006){ref-type="table"}).

Contrarily, the difference of the two groups in Task 3 "Defining the conditional structure" and in Task 4 "Creating categories" is not statistically significant.

Given these results, it is possible to give credit to the study hypothesis: patients with TS exhibit higher creative scores when compared with individuals with PD.

3.2. ASK Results of the Sample in Score Ranges {#sec3dot2-brainsci-07-00080}
----------------------------------------------

ASK manual reports three score ranges for the subtest "Creative Thinking": low score range (below 93 points); average score range (between 93 and 07 points); high score range (over 107 points).

The study analysis has been carried out on 54 subjects, i.e., 27 patients with PD and 27 patients suffering from TS. The number of subjects with PD who have obtained a score of less than 93 points is *n* = 14 (51.9% of the subjects with PD) compared with *n* = 5 subjects in TS group, that is, 18.5% of subjects with TS ([Table 7](#brainsci-07-00080-t007){ref-type="table"}).

The number of PD subjects achieving a score between 93 and 107 points is *n* = 10 (37% of the subjects with PD), compared with *n* = 14 subjects in TS group, that is, 51.9% of patients with TS ([Table 7](#brainsci-07-00080-t007){ref-type="table"}).

Finally, the number of subjects with PD who scored higher than 107 points is *n* = 3 (11.1% of the subjects with PD) compared with *n* = 8 in TS group, that is, 29.6% of patients with TS ([Table 7](#brainsci-07-00080-t007){ref-type="table"}).

Therefore, individuals with PD and TS are differently positioned in the three ranges of scores: in particular, those with TS are positioned on average in the upper range, i.e., resulting in over 107 points, while subjects with PD are placed on average in the lower range, i.e., resulting below 93 points ([Table 7](#brainsci-07-00080-t007){ref-type="table"}).

At last, [Table 6](#brainsci-07-00080-t006){ref-type="table"} and [Table 7](#brainsci-07-00080-t007){ref-type="table"} give credit to the initial hypothesis: TS patients result in having higher creative scores than PD patients.

Considering other possible results, no significant differences concerning creative assessments in the two groups have been found in relation to age and sex.

3.3. Discussion {#sec3dot3-brainsci-07-00080}
---------------

Although the study hypothesis has been confirmed, many considerations are needed about strengths and limitations of the study itself.

First, mean age difference between patients is one of the limitations of the study. The limitation is due to the different age of development of the two diseases: childhood and adolescence of TS and adulthood of PD. We opted for a range age of 35--57 years old in order to terminate the study in approximately two years (2014--2016).

Secondly, considering the ongoing treatments, the sample was too heterogeneous (type of drugs, DBS targets, DBS settings) to produce a comparison between subjects. Researchers have therefore been limited to note the type of intervention in progress. Therapy difference between subjects is a limitation of the study because they could have had an effect on the sample's dopamine levels and, therefore, on the creativity assessment. However, it remains unclear in which way treatments had modulated creativity in each pathology. Probably, medications worked against the study hypothesis because antidopaminergic treatments in TS group should have reduced creativity while reducing symptoms.

However, as PD and TS patients usually undergo heterogeneous therapies, our sample is considered a "reachable sample" in an ordinary hospital. Again, we opted for a sample with heterogeneous therapies because homogeneous therapy groups of patients would have meant a longer period of recruitment and/or the necessity of involving multiple centres in the study.

Geographical area of recruitment was limited to Italy, and patients were coming from only two centres. We decided to concentrate this study at the Galeazzi Hospital and the Mondino Institute.

For the above-mentioned limitations, the study is considered as a preliminary study.

4. Conclusions {#sec4-brainsci-07-00080}
==============

This study supported our hypothesis of highlighting a predisposition to creativity in patients with TS rather than in PD patients. Actually, TS creative scores were higher than PD creative scores; therefore, the aim of the study has been reached.

During the clinical assessment, creativity can be a useful element for the differential diagnosis of TS and PD. Consequently, further studies are needed about creativity in TS even in childhood and adolescence.

Considering interventions, the psychosocial intervention for both patients with TS and PD should take into account the creative factor to be further stimulated in TS, and to be increased in PD. Art therapy, including music therapy and theatre, are just a few examples of psychosocial intervention to be considered in TS and PD patients.

The main limitation of the study consisted in the comparison of a neurodevelopment disorder (TS) with a neurodegenerative disorder (PD) because of the significant age difference of the two groups, and therefore the lack of an age-matched sample. This limitation leads to preliminary results that need to be integrated with results of bigger samples and/or with a smaller age range of the sample. Furthermore, the heterogeneity of therapies of patients is another limitation for the comparison of the two groups because of the possible effect of therapies on patients' creative assessment. Actually, it is possible that the medication intake works against our hypothesis: TS group receives medications that block dopaminergic activity and, as a result, creativity should also diminish. Again, this limitation leads to preliminary results that need to be integrated with results of homogeneous therapy groups of patients. For these reasons, the current study can be considered a preliminary study. Conversely, the absence of any literature comparing creative traits in PD and TS is the principal strength of the current study.

Further multi-centre studies are needed with larger samples of age-matched subjects and/or from different geographic areas and/or with single or multiple homogeneous therapies, in order to extend our preliminary results. A study on the discussion of different comorbidities of TS in relation to creativity will be realised by our group in the future.

The authors would like to thank Claudio Pacchetti, Marta Picascia, Palmira Faraci, Silvia Clarotti and Tabata Pomilia for their collaboration. Clinical and Research Galeazzi Hospital's funds covered the costs to publish in open access.
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brainsci-07-00080-t001_Table 1

###### 

Age, The Yale Global Tic Severity Scale (YGTSS) \[[@B38-brainsci-07-00080]\] score and ongoing treatments of Tourette Syndrome (TS) sample. \* DBS = Deep Brain Stimulation.

  TS Patient N   Age (years) at the Test Administration   YGTSS \[[@B38-brainsci-07-00080]\] Score at the Test Administration   Ongoing Treatments (No Treatment-Psychotherapy-Drugs-DBS \*)   Type of Drugs and Posology
  -------------- ---------------------------------------- --------------------------------------------------------------------- -------------------------------------------------------------- -----------------------------------------------------------------------------
  1              42                                       45                                                                    Drugs + DBS                                                    aripiprazole 15 mg − quetiapine 25 mg
  2              56                                       40                                                                    No treatment                                                   
  3              44                                       68                                                                    Psychotherapy + drugs                                          alprazolam 0.5 mg
  4              57                                       26                                                                    No treatment                                                   
  5              44                                       20                                                                    No treatment                                                   
  6              43                                       31                                                                    No treatment                                                   
  7              37                                       50                                                                    Drugs + DBS                                                    aripiprazole 15 mg
  8              35                                       27                                                                    No treatment                                                   
  9              51                                       63                                                                    Drugs                                                          escitalopram 10 mg − alprazolam 0.5 mg
  10             41                                       49                                                                    Drugs                                                          aripiprazole 15 mg − topiramate 25 mg
  11             35                                       51                                                                    Drugs                                                          aripiprazole 15 mg − fluvoxamine 100 mg
  12             35                                       28                                                                    No treatment                                                   
  13             46                                       62                                                                    Drugs                                                          clomipramine 75 mg − ketazolam 30 mg × 2 die
  14             41                                       33                                                                    No treatment                                                   
  15             38                                       41                                                                    Drugs                                                          tetrabenazine 25 mg × 3 die
  16             37                                       48                                                                    Drugs + DBS                                                    aripiprazole 15 mg
  17             35                                       57                                                                    Drugs                                                          risperidone 1 mg × 2 die
  18             35                                       59                                                                    Drugs                                                          pimozide 4 mg − aripiprazole 25 mg
  19             50                                       61                                                                    Drugs                                                          citalopram 25 mg
  20             49                                       64                                                                    Drugs                                                          topiramate 25 mg − tiapride hydrochloride 100 mg × 2 die − duloxetine 30 mg
  21             46                                       48                                                                    Drugs                                                          aripiprazole 15 mg − clomipramine 25 mg
  22             37                                       51                                                                    Drugs                                                          pimozide 4 mg
  23             44                                       60                                                                    Drugs                                                          pimozide 4 mg
  24             35                                       23                                                                    No treatment                                                   
  25             35                                       52                                                                    Drugs                                                          pimozide 4 mg
  26             49                                       34                                                                    No treatment                                                   
  27             35                                       55                                                                    Drugs                                                          pimozide 4 mg

brainsci-07-00080-t002_Table 2

###### 

Age, Unified Parkinson's Disease Rating Scale (UPDRS) \[[@B39-brainsci-07-00080]\] score and ongoing treatments of PD sample.

  PD Patient N   Age (Years) at the Test Administration   UPDRS \[[@B39-brainsci-07-00080]\] Score at the Test Administration   Ongoing Treatments (Drugs-DBS \*)   Type of Drugs and Posology
  -------------- ---------------------------------------- --------------------------------------------------------------------- ----------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1              56                                       96                                                                    Drugs                               pramipexole ER 0.26 mg
  2              57                                       68                                                                    Drugs + DBS                         ropinirole 4 mg − rasagiline 1 mg
  3              40                                       58                                                                    Drugs + DBS                         ropinirole 4 mg − rasagiline 1 mg
  4              57                                       102                                                                   Drugs                               rasagiline 0.5 mg − pramipexole ER 0.26 mg − carbidopa hydrate 27 mg − melevodopa hydrochloride 314 mg
  5              54                                       99                                                                    Drugs                               levodopa 100 mg − carbidopa 25 mg − fluvoxamine 100 mg
  6              57                                       75                                                                    Drugs + DBS                         levodopa 50 mg × 4 die − benserazide 12.5 mg × 4 die
  7              57                                       122                                                                   Drugs                               levodopa 100 mg × 4 die − carbidopa 25 mg × 4 die − entacapone 200 mg × 4 die
  8              48                                       118                                                                   Drugs                               levodopa 100 mg × 3 die − carbidopa 25 mg × 3 die − entacapone 200 mg × 3 die − rasagiline 1 mg − thiamine 300 mg × 2 die − folic acid 5 mg
  9              52                                       61                                                                    Drugs + DBS                         carbidopa hydrate 27 mg − melevodopa hydrochloride 125.6 mg − rotigotine 2 mg + duloxetine 60 mg + folic acid 5mg
  10             46                                       64                                                                    Drugs + DBS                         levodopa 100 mg × 3 die − benserazide 25 × 3 die − rotigotine 4 mg
  11             56                                       139                                                                   Drugs                               levodopa 75 mg × 4 die − carbidopa 18.75 mg × 4 die − entacapone 200 mg × 4 die − fluvoxamine 50 mg − rotigotine 8 mg
  12             57                                       116                                                                   Drugs                               carbidopa hydrate 13.5 mg − melevodopa hydrochloride 157 mg − pramipexole ER 0.26 mg − levodopa 100 mg − carbidopa 25 mg − rasagiline 1 mg
  13             56                                       131                                                                   Drugs                               levodopa 75 mg × 3 die − carbidopa 18.75 mg × 3 die − entacapone 200 mg × 3 die − carbidopa hydrate 27 mg × 4 die − melevodopa hydrochloride 125.6 mg × 4 die, ramipril 2.5 mg, venlafaxine 75 mg
  14             44                                       52                                                                    Drugs + DBS                         ropinirole 4 mg − rasagiline 1 mg
  15             57                                       97                                                                    Drugs                               levodopa 200 mg × 3 die − benserazide 50 mg × 3 die − rasagiline 1 mg − ropinirole ER 8 mg − mirabegron 50 mg
  16             55                                       111                                                                   Drugs                               pramipexole 0.7 mg − levodopa 125 mg × 3 die − carbidopa 31.25 mg × 3 die − entacapone 200 mg × 3 die
  17             56                                       73                                                                    Drugs                               pramipexole 0.52 mg − pramipexole 0.26 × 2 die
  18             46                                       81                                                                    Drugs                               rotigotine 4 mg − levodopa 100 mg × 4 die − carbidopa 25 mg × 4 die − entacapone 200 mg × 4 die
  19             56                                       101                                                                   Drugs                               levodopa 100 mg × 4 die − carbidopa 25 mg × 4 die − entacapone 200 mg × 4 die
  20             57                                       49                                                                    Drugs + DBS                         carvedilol 25 mg
  21             56                                       114                                                                   Drugs                               levodopa 75 mg × 3 die − carbidopa 18.75 mg × 3 die − entacapone 200 mg × 3 die − carbidopa hydrate 27 mg × 4 die − melevodopa hydrochloride 125.6 mg × 4 die
  22             57                                       58                                                                    Drugs + DBS                         ropinirole 4 mg − rasagiline 1 mg
  23             44                                       67                                                                    Drugs                               rasagiline 1 mg
  24             51                                       75                                                                    Drugs                               pramipexole 0.52 mg − duloxetine 30 mg
  25             56                                       111                                                                   Drugs                               levodopa 100 mg × 3 die − benserazide 25 mg × 3 die − rasagiline 1 mg
  26             49                                       70                                                                    Drugs                               pramipexole 1.05 mg
  27             55                                       117                                                                   Drugs                               levodopa 50 mg × 4 die − benserazide 12.5 mg × 4 die

\* DBS = Deep Brain Stimulation.

brainsci-07-00080-t003_Table 3

###### 

Sample average age and standard deviation.

                             N° of Subjects (%)   Average Age   Standard Deviation
  -------------------------- -------------------- ------------- --------------------
  Parkinson Disease sample   27 (50%)             53.03         5.09
  Tourette Syndrome sample   27 (50%)             41.92         6.77
  Total sample               54 (100%)            47.48         8.16

brainsci-07-00080-t004_Table 4

###### 

Gender of the sample.

                 Diagnosis    Total        
  -------------- ------------ ------------ -----------
  Male           20 (55.6%)   16 (44.4%)   36 (100%)
  Female         7 (38.9%)    11 (61.1%)   18 (100%)
  Total sample   27 (50%)     27 (50%)     54 (100%)

brainsci-07-00080-t005_Table 5

###### 

Average YGTSS and UPDRS scores of the sample.

          Average Scores   Standard Deviation
  ------- ---------------- --------------------
  YGTSS   46.14            14.07
  UPDRS   89.81            26.38

brainsci-07-00080-t006_Table 6

###### 

Average scores of the sample in the four tasks and average total score.

  Diagnosis               Average Score Task 1 ± S.D.   Average Score Task 2 ± S.D.   Average Score Task 3 ± S.D.   Average Score Task 4 ± S.D.   Average Total Score ± S.D.
  ----------------------- ----------------------------- ----------------------------- ----------------------------- ----------------------------- ----------------------------
  Parkinson Disease       93.6 ± 7.4                    95.5 ± 8.2                    97.9 ± 9.8                    97.0 ± 10.9                   94.4 ± 10.0
  Tourette Syndrome       99.7 ± 9.7                    102.1 ± 8.3                   103.9 ± 13.1                  101.4 ± 9.2                   103.1 ± 13.0
  Sig. Asint. Two-sided   0.011 \*                      0.003 \*                      0.094                         0.129                         0.019 \*

\* = the scores of the two groups have a statistically significant difference.
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###### 

Results of the sample in score ranges.

  Contingency Table                                                                    
  ---------------------------------- ------------------------ ---------- -------- ---- ----
  Score range                        Score range 1 below 93   Counting   14       5    19
  %within totscore3                  73.7%                    26.3%      100.0%        
  %within diagnosis                  51.9%                    18.5%      35.2%         
  Score range 2 between 93 and 107   Counting                 10         14       24   
  %within totscore3                  41.7%                    58.3%      100.0%        
  %within diagnosis                  37.0%                    51.9%      44.4%         
  Score range 3 over \>107           Counting                 3          8        11   
  %within totscore3                  27.3%                    72.7%      100.0%        
  %within diagnosis                  11.1%                    29.6%      20.4%         
  Total                              Counting                 27         27       54   
  %within totscore3                  50.0%                    50.0%      100.0%        
  %within diagnosis                  100.0%                   100.0%     100.0%        
